Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn's Disease: Determinants of Higher Adherence and Response.


Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
01 09 2023
Historique:
received: 10 01 2022
medline: 10 10 2023
pubmed: 13 10 2022
entrez: 12 10 2022
Statut: ppublish

Résumé

Exclusive enteral nutrition (EEN) is the first choice to induce remission and promote mucosal healing in pediatric Crohn's disease (CD). However, full adherence to EEN treatment may be problematic for children with CD. The goal of the current multicenter retrospective study was to define predictive factors of nonadherence to treatment and nonremission at the end of induction treatment. Those data together were analyzed with the ultimate goal of trying to define an individualized induction treatment for children with CD. Three hundred seventy-six children with CD from 14 IBD pediatric referral centers were enrolled in the study. The rate of EEN adherence was 89%. Colonic involvement and fecal calprotectin >600 μg/g at diagnosis were found to be associated with a reduced EEN adherence. Exclusive enteral nutrition administered for 8 weeks was effective for inducing clinical remission in 67% of the total cohort. Factors determining lower remission rates were age >15 years and Pediatric Crohn's Disease Activity Index >50. Although EEN is extremely effective in promoting disease remission, several patients' related factors may adversely impact EEN adherence and response. Personalized treatments should be proposed that weigh benefits and risks based on the patient's disease location, phenotype, and disease activity and aim to promote a rapid control of inflammation to reduce long-term bowel damage.

Sections du résumé

BACKGROUND
Exclusive enteral nutrition (EEN) is the first choice to induce remission and promote mucosal healing in pediatric Crohn's disease (CD). However, full adherence to EEN treatment may be problematic for children with CD.
METHODS
The goal of the current multicenter retrospective study was to define predictive factors of nonadherence to treatment and nonremission at the end of induction treatment. Those data together were analyzed with the ultimate goal of trying to define an individualized induction treatment for children with CD.
RESULTS
Three hundred seventy-six children with CD from 14 IBD pediatric referral centers were enrolled in the study. The rate of EEN adherence was 89%. Colonic involvement and fecal calprotectin >600 μg/g at diagnosis were found to be associated with a reduced EEN adherence. Exclusive enteral nutrition administered for 8 weeks was effective for inducing clinical remission in 67% of the total cohort. Factors determining lower remission rates were age >15 years and Pediatric Crohn's Disease Activity Index >50.
CONCLUSION
Although EEN is extremely effective in promoting disease remission, several patients' related factors may adversely impact EEN adherence and response. Personalized treatments should be proposed that weigh benefits and risks based on the patient's disease location, phenotype, and disease activity and aim to promote a rapid control of inflammation to reduce long-term bowel damage.

Identifiants

pubmed: 36222487
pii: 6759350
doi: 10.1093/ibd/izac215
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1380-1389

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Marialaura Cuomo (M)

Department of Pediatrics, San Carlo Hospital - ASST Santi Paolo e Carlo, Milano, Italy.

Alessandra Carobbio (A)

FROM Research foundation, ASST Papa Giovanni XXIII, Bergamo, Italy.

Marina Aloi (M)

Pediatric Gastroenterology and Liver Unit, Department of Maternal and Child Health, Sapienza University of Rome, Roma, Italy.

Patrizia Alvisi (P)

Pediatric Gastroenterology Unit, Maggiore Hospital, Bologna, Italy.

Claudia Banzato (C)

Pediatric Clinic, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Pediatric Division, University of Verona, Verona, Italy.

Luca Bosa (L)

Department of Women's and Children's Health, University of Padova, Padova, Italy.

Matteo Bramuzzo (M)

Institute for Maternal and Child Health "IRCCS Burlo Garofolo", Trieste, Italy.

Angelo Campanozzi (A)

Pediatrics, Department of Medical and Surgical Sciences, University of Foggia, Italy.

Giulia Catassi (G)

Pediatric Gastroenterology and Liver Unit, Department of Maternal and Child Health, Sapienza University of Rome, Roma, Italy.

Lorenzo D'Antiga (L)

Pediatric Hepatology, Gastroenterology and Transplantation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.

Monica Di Paola (M)

Gastroenterology and Nutrition Unit, Meyer children's Hospital, Department Neurofarba, University of Florence, Florence, Italy.

Enrico Felici (E)

Pediatric and Pediatric Emergency Unit, "U. Bosio" Center for Pediatric Digestive Diseases, Children Hospital, AO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.

Maria Teresa Fioretti (MT)

Department of Translational Medical Science, Section of Pediatrics, University of Naples "Federico II", Napoli, Italy.

Simona Gatti (S)

Department of Pediatrics, Polytechnic University of Marche, G. Salesi Children's Hospital, Ancona, Italy.

Francesco Graziano (F)

Pediatric Unit, Villa Sofia Cervello Hospital, Palermo-Italy, Italy.

Sara Lega (S)

Institute for Maternal and Child Health "IRCCS Burlo Garofolo", Trieste, Italy.

Paolo Lionetti (P)

Pediatrics, Department of Medical and Surgical Sciences, University of Foggia, Italy.

Antonio Marseglia (A)

Division of Pediatrics, "IRCCS Casa Sollievo della Sofferenza", San GiovanniRotondo, Italy.

Massimo Martinelli (M)

Gastroenterology and Nutrition Unit, Meyer children's Hospital, Department Neurofarba, University of Florence, Florence, Italy.

Francesca Musto (F)

Pediatric Department, University of Milano Bicocca, Fondazione MBBM, Onlus San Gerardo Hospital, Monza, Italy.

Naire Sansotta (N)

Pediatric Hepatology, Gastroenterology and Transplantation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.

Luca Scarallo (L)

Pediatrics, Department of Medical and Surgical Sciences, University of Foggia, Italy.

Giovanna Zuin (G)

Pediatric Department, University of Milano Bicocca, Fondazione MBBM, Onlus San Gerardo Hospital, Monza, Italy.

Lorenzo Norsa (L)

Pediatric Hepatology, Gastroenterology and Transplantation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH